Abstract

MYH9-related disease or disorder (MYH9-RD) is an autosomal dominant disease caused by mutations in the MYH9 gene. Mutations in this gene initially affect the hemic system, and other manifestations may evolve with age. Here, we report the case of a 46-year-old Chinese woman with MYH9-RD who was primarily misdiagnosed with idiopathic thrombocytopenia purpura. Exome sequencing of the patient, and the mother and son of the patient revealed a deletion mutation c.5797delC (p. R1933Efs*15) in exon 41 (encoding non-helical tailpiece, NHT) of the MYH9 gene, which consequently led to a frameshift mutation. To the best of our knowledge, this mutation has been reported in Italy once, while the substitution mutation c.5797 C>T is the most frequent mutation. Mutations that affect the NHT region cause thrombocytopenia throughout life; however, our patient presented with a more severe phenotype than previously reported, including thrombocytopenia, inclusion bodies in neutrophils, sensorineural hearing loss, nephropathy, and abnormal liver enzymes. Our goal in the current case is to prevent further progression of renal involvement and to identify other affected members in this family to provide early intervention. This case may raise awareness of MYH9-RD when diagnosing thrombocytopenia and improve our understanding of this condition.

Highlights

  • The human MYH9 gene is located on chromosome 22q12.3 and encodes non-muscle myosin heavy chain IIA, which is widely expressed in more than 27 different tissues

  • Each heavy chain comprises two domains: the N-terminal head domain (HD), which consists of a global motor domain and a neck domain, and a C-terminal tail domain (TD), including a long α-helical coiled-coil region ending with a non-helical tailpiece (NHT) (Pecci et al, 2018)

  • The clinical picture of MYH9-related disease or disorder (MYH9-RD) is characterized by hematologic features consisting of platelet macrocytosis, thrombocytopenia, and inclusion bodies in neutrophil granulocytes, which are present at birth in all affected individuals, while some patients develop one or more extrahematological manifestations, including sensorineural deafness, cataract, and nephropathy, which eventually lead to end-stage renal disease (ESRD)

Read more

Summary

INTRODUCTION

The human MYH9 gene is located on chromosome 22q12.3 and encodes non-muscle myosin heavy chain IIA, which is widely expressed in more than 27 different tissues. The clinical picture of MYH9-RD is characterized by hematologic features consisting of platelet macrocytosis, thrombocytopenia, and inclusion bodies in neutrophil granulocytes, which are present at birth in all affected individuals, while some patients develop one or more extrahematological manifestations, including sensorineural deafness, cataract, and nephropathy, which eventually lead to end-stage renal disease (ESRD). Detailed examination revealed similar results as above: a platelet count of 27 × 109/L, urine protein level of “3+,” and serum creatinine level of 265 μmol/L [estimated glomerular filtration rate (GFR), 18 ml/min). Another laboratory finding was elevated liver enzymes with an alanine aminotransferase (ALT) level of 78 U/L and aspartate aminotransferase (AST) level of 62 U/L. Arginine is an evolutionarily conserved amino acid in this protein among different organisms (Figure 3B), which indicates that changes in amino acids at this site may affect protein function

DISCUSSION
Findings
ETHICS STATEMENT
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call